Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Flatiron Health

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

Combination therapies in oncology: The benefits of integrated insights

14 June 2018 11am EDT | 8am PDT | 4pm BST | 5pm CE

Research Partnership

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

- PMLiVE

AbbVie trial backs chemo-free Imbruvica combo regimen

Imbruvica paired with Roche’s Gazyva for previously untreated CLL patients

- PMLiVE

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Latest data could unlock a new patient population for the Swiss pharma giant’s injection

- PMLiVE

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

A rapid round-up of pharma, biotech and healthcare news

Eli Lilly HQ

Lilly adds AurKa Pharma to oncology buying spree

Lilly is buying back its former drug after just two years

Roche Basel Switzerland

Another IO knockback as Tecentriq combo fails phase III trial

The bulk of CRC patients with MSS currently look set to be excluded from cancer immunotherapy

Eli Lilly HQ

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo is developing IL-10 drugs for potential combination with established immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links